Merrimack to Present Multiple Posters at the 2012 American Association for Cancer Research Conference "Pancreatic Cancer: Progress and Challenges" Preclinical data on the mechanism of action of MM-398 in pancreatic cancer will be presented Preclinical data on MM-398's extended pharmacological profile will be presented Preclinical data on...

Merrimack Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference CAMBRIDGE, Mass., May 31, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President and Chief Executive Officer, is scheduled to present at...

Merrimack to Present Multiple Posters at the 2012 Annual Meeting of the American Society of Clinical Oncology Data on the safety and initial activity of MM-121 combined with erlotinib to be presented MM-111 multi-arm combination and MM-302 monotherapy Phase 1 designs to be presented CAMBRIDGE, Mass.,...

Merrimack Pharmaceuticals Reports First Quarter 2012 Financial Results CAMBRIDGE, Mass., May 15, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...

Merrimack Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference CAMBRIDGE, Mass., May 10, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President and Chief Executive Officer, is scheduled to present at...